Featured Research

from universities, journals, and other organizations

Stem Cells May Gradually Replace Antirejection Drugs For Kidney Transplant Patients

Date:
January 24, 2008
Source:
Northwestern Memorial Hospital
Summary:
After transplant surgery, antirejection drugs for the organ recipient are a must. But prolonged use can have serious side effects, including infections, heart disease and even cancer. A new study seeks to eliminate the need for antirejection drugs by transplanting stem cells from a kidney donor's bone marrow into the organ recipient.

After a transplant surgery, anti-rejection drugs for the organ recipient are a must, but with prolonged use can have serious side effects, including infections, heart disease and cancer. A team led by Joshua Miller, MD, a researcher at Northwestern University's Feinberg School of Medicine, is working with Northwestern Memorial Hospital's department of organ transplantation to enroll qualifying subjects in a new research study that seeks to transplant stem cells from a kidney donor's bone marrow into the recipient, with the hope of gradually eliminating the need for anti-rejection drugs. If research proves successful, it would mean a dramatic change in the post-transplant quality of life for the transplant recipient.

Related Articles


Northwestern is the only center in Chicago and one of four centers nationally looking at this topic. The Feinberg School of Medicine has received a four-year, $2.5 million grant from the National Institutes of Health to enroll 20 patients in the study, which is called "Donor Stem Cells, Campath, T/B Cell Regulation In HLA-Identical Renal Transplants."

The first subjects to participate in the study underwent kidney transplant surgery on Thursday, Jan. 10. Sharon Flood of Pingree Grove, Ill. donated her kidney to her brother Steven Yelk of Gurnee, Ill., who suffers from polycystic kidney disease (PKD), which causes cysts filled with fluid to form throughout the kidneys. Eventually, these cysts take over the healthy kidney tissue and the kidneys fail. "Our family is very close and there are seven brothers and sisters, I was thrilled to learn that I was a match and would be able to help Steven," Sharon commented before the surgery.

Joseph Leventhal, MD, PhD, transplant surgeon, associate professor of surgery and director of the Living Donor Renal Transplant Program at Northwestern University's Feinberg School of Medicine, preformed the kidney donor's surgery and Michael Abecassis, MD, MBA, chief of the division of transplantation, and dean of clinical affairs for Northwestern University's Feinberg School of Medicine, performed the recipient's surgery.

"The surgery was successful, everything went according to plan and the new kidney is functioning well," said Dr. Abecassis. From here, the kidney recipient will begin the experimental portion of the study.

This study is open to HLA-identical sibling kidney donor and recipient pairs. HLA, or human leukocyte antigen, is one of a group of proteins found on the surface of white blood cells and other cells that play an important part in the body's immune response to foreign substances. These antigens vary from person to person, and an HLA compatibility test is performed before organ transplantation to find out if tissues match between a donor and a recipient.

The study is limited to only HLA-identical sibling pairs because these siblings genetically have a more similar set of immunologic markers than a non-related HLA-identical pair. Because this population has the closest genetic relationship, they have the best chance for success with the study. Overall, HLA-identical siblings have very low rejection rates for kidney transplants but until now have still required immunosuppressive drugs to be taken for life.

How does it work?

Stem cells are formed at the marrow and are common blood cells from which other specialized blood cells, like immune cells, develop. These stem cells are considered important to help prevent rejection of the kidney transplant. By transplanting these cells from the kidney donor into the recipient, the study seeks to prove that the stem cells will mature in the recipient's body and will allow his immune system to accept the new organ as his own.

For the kidney donor, the laparoscopic surgery occurs in the standard manner. After the kidney is removed, bone marrow is drawn from the donor's hip bone. About three months following the surgery, the donor undergoes two procedures called leukopheresis, happening one day apart, where stem cells mobilized from the marrow are collected so that they can be given to the kidney recipient to help his body acclimate to the transplant.

Approximately one month before the transplant surgery, the recipient undergoes leukopheresis to draw white blood cells which are stored in a lab for later testing. After transplant surgery, the recipient receives four separate infusions of donor stem cells.

The stem cells are infused into the transplant recipient via an IV in a procedure that lasts about 15 minutes. The first infusion is five days after surgery, the next is about three months after surgery, then six months and finally nine months after the transplant. During this time the recipient is treated with Campath-1H, a potent antibody used extensively at Northwestern to prevent rejection, in addition to the other standard anti-rejection medications. About a year after the surgery, the subject is weaned off of one anti-rejection drug, then another. There are also ongoing tests to ensure the recipient is tolerating the kidney.

"This is an exciting area of research which holds a great deal of promise if successful," says Dr. Abecassis. "We are excited to be the only center in the region offering this to qualifying patients."


Story Source:

The above story is based on materials provided by Northwestern Memorial Hospital. Note: Materials may be edited for content and length.


Cite This Page:

Northwestern Memorial Hospital. "Stem Cells May Gradually Replace Antirejection Drugs For Kidney Transplant Patients." ScienceDaily. ScienceDaily, 24 January 2008. <www.sciencedaily.com/releases/2008/01/080123125623.htm>.
Northwestern Memorial Hospital. (2008, January 24). Stem Cells May Gradually Replace Antirejection Drugs For Kidney Transplant Patients. ScienceDaily. Retrieved April 1, 2015 from www.sciencedaily.com/releases/2008/01/080123125623.htm
Northwestern Memorial Hospital. "Stem Cells May Gradually Replace Antirejection Drugs For Kidney Transplant Patients." ScienceDaily. www.sciencedaily.com/releases/2008/01/080123125623.htm (accessed April 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, April 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) — Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com
Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins